Opinion|Videos|December 14, 2023
Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments
The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
Five Under 5: Top Oncology Videos for the Week of 8/2
4
Revisit Every OncLive On Air Episode From July 2026
5